# Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria

> **NIH NIH U01** · COLORADO STATE UNIVERSITY · 2020 · $684,788

## Abstract

Project Summary / Abstract
Enhanced malaria control efforts since the turn of the century have resulted in notable reductions in malaria
morbidity and mortality. This success has been driven by the widespread distribution of long-lasting insecticide
treated nets and targeted indoor residual spraying of insecticides to combat vectors as well as rapid diagnosing
and treatment of malaria with artemesisin-based combination therapies, and chemoprevention programs for
pregnant women and children. However, malaria control efforts are stagnating because programs targeting both
the vector and the parasite are not well integrated, and the efficacy of both is severely threatened by widespread
resistance of vectors to currently-approved insecticides and spreading resistance of parasites to currently-
approved drugs. We hypothesize that malaria control can be enhanced, and the spread of both insecticide
resistance and antimalarial drug resistance can be curtailed, if vector and parasite control efforts are linked using
the endectocide ivermectin that can target both organisms with another layer of combination therapy to each.
Ivermectin is an antiparasitic drug that is safe and distributed to hundreds of millions of humans each year. It
also efficiently kills malaria vectors that blood feed on treated people and strong evidence suggests it also has
activity against the sporogonic and exoerythrocytic stages of Plasmodium. We will conduct a cluster randomized
clinical trial in Burkina Faso to test whether repeated ivermectin mass drug administrations, integrated into a
monthly delivery platform with the standard malaria control measures of seasonal malaria chemoprevention and
insectide-treated bed net distribution in the Sahel, will reduce childhood malaria incidence and limit resistance
in both mosquitoes and parasites.

## Key facts

- **NIH application ID:** 9987501
- **Project number:** 5U01AI138910-03
- **Recipient organization:** COLORADO STATE UNIVERSITY
- **Principal Investigator:** BRIAN David FOY
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $684,788
- **Award type:** 5
- **Project period:** 2018-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9987501

## Citation

> US National Institutes of Health, RePORTER application 9987501, Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria (5U01AI138910-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9987501. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*